Journal
LANCET
Volume 371, Issue 9617, Pages 1030-1043Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(08)60457-2
Keywords
-
Categories
Funding
- NCI NIH HHS [CA51001, P30 CA006516, CA21765, CA78224, CA68484, CA06516, CA60419, CA36401, CA90246, CA52259] Funding Source: Medline
- NIGMS NIH HHS [GM61393] Funding Source: Medline
- NINR NIH HHS [NR07610] Funding Source: Medline
Ask authors/readers for more resources
Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-firee survival while reducing the toxic side-effects of current intensive regimens. Advances in our understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease. Meanwhile, studies are underway to ascertain the precise events that take place in the genesis of acute lymphoblastic leukaemia, to enhance the clinical application of known risk factors and antileukaemic agents, and to identify treatment regimens that might boost the generally low cure rates in adults and subgroups of children with high-risk leukaemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available